Update: Acute coronary syndromes (V). Personalized antiplatelet therapy.
It is well established that high on-treatment platelet reactivity to adenosine diphosphate during clopidogrel therapy is an independent risk factor for ischemic event occurrences in a postpercutaneous coronary intervention patients. However, the precise role of platelet function testing remains debated. Platelet function testing to ensure optimal platelet inhibition has been recommended by some authorities to improve outcomes in patients treated with clopidogrel. Recent prospective, randomized trials of personalized antiplatelet therapy have failed to demonstrate a benefit of platelet function testing in improving outcomes. In this review article, we discuss the mechanisms responsible for clopidogrel nonreponsiveness, recent trials of platelet function testing, and other new developments in the field of personalized antiplatelet therapy.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Treatment Failure
- Ticlopidine
- Randomized Controlled Trials as Topic
- Precision Medicine
- Platelet Aggregation Inhibitors
- Humans
- Clopidogrel
- Acute Coronary Syndrome
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Treatment Failure
- Ticlopidine
- Randomized Controlled Trials as Topic
- Precision Medicine
- Platelet Aggregation Inhibitors
- Humans
- Clopidogrel
- Acute Coronary Syndrome